In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Bettina SeydelDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Philipp HegnerDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0003-1776-777X Anna-Maria LauererDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0009-0007-5054-3854 Sönke SchildtDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0001-7245-6902 Fatma BayramDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0009-0003-7230-3473 Maria TafelmeierDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0003-3778-6716 Dominik WermersDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Leopold RupprechtDepartment of Cardiothoracic Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0003-1188-6460 Christof SchmidDepartment of Cardiothoracic Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
Stefan WagnerDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-9471-1166 Lars Siegfried MaierDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0001-9915-4429 Michael ArztDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Simon LebekDepartment of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0003-4525-797X Funding
Else-Kröner-Fresenius Foundation n/aElse-Kröner-Fresenius Foundation project number: 2018_A159EU Horizon grant STRATIFY-HF project number: 101080905German Cardiac Society Clinician Scientist ProgramGerman Federal Ministry of Education and Research project number: 01ZZ2324CGerman Heart Foundation n/aGerman Research Foundation HE 10029/1-1, project number: 554804344German Research Foundation Heisenberg-Professorship (LE 5009/2-1, project number: 528296867)German Research Foundation LE 5009/3-1, project number: 528297116German Research Foundation LE 5009/5-1, project number: 554804344German Research Foundation TRR 374 grant (project number: 509149993, TPA6)German Research Foundation WA 2539/8-1
6 · The paper itselfAbstract
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide, underscoring the urgent need for novel therapeutic targets and strategies. The kinase MARK4 (MAP (microtubule-associated proteins)/microtubule affinity-regulating kinase 4) regulates microtubule-associated proteins pivotal for cell polarity, protein stability, and intracellular signaling. Animal models of heart failure revealed elevated MARK4 levels, which correlated with impaired cardiac contractility. However, the involvement of MARK4 and its potential as a molecular drug target has not yet been explored in the myocardium of cardiovascular patients. We investigated the
Indexed as
Heart FailureMyocardiumProtein Serine-Threonine KinasesSleep Apnea SyndromesAgedEchocardiographyFemaleHumansMaleMiddle AgedProtein Serine-Threonine Kinasesbiomarkerscardiovascular diseasedrug targetsheart failurehypoxiaMARK4
Identifiers
PMID40332117
PMCPMC12027440
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390